Unknown

Dataset Information

0

4-aminopyridine reverses ataxia and cerebellar firing deficiency in a mouse model of spinocerebellar ataxia type 6.


ABSTRACT: Spinocerebellar ataxia type 6 (SCA6) is a devastating midlife-onset autosomal dominant motor control disease with no known treatment. Using a hyper-expanded polyglutamine (84Q) knock-in mouse, we found that cerebellar Purkinje cell firing precision was degraded in heterozygous (SCA6(84Q/+)) mice at 19 months when motor deficits are observed. Similar alterations in firing precision and motor control were observed at disease onset at 7 months in homozygous (SCA6(84Q/84Q)) mice, as well as a reduction in firing rate. We further found that chronic administration of the FDA-approved drug 4-aminopyridine (4-AP), which targets potassium channels, alleviated motor coordination deficits and restored cerebellar Purkinje cell firing precision to wildtype (WT) levels in SCA6(84Q/84Q) mice both in acute slices and in vivo. These results provide a novel therapeutic approach for treating ataxic symptoms associated with SCA6.

SUBMITTER: Jayabal S 

PROVIDER: S-EPMC4933933 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC2288764 | biostudies-literature
| S-EPMC9407720 | biostudies-literature
| S-EPMC4697081 | biostudies-other
| S-EPMC9563426 | biostudies-literature
| S-EPMC9576077 | biostudies-literature
| S-EPMC5983343 | biostudies-literature
| S-EPMC7983976 | biostudies-literature
| S-EPMC10715727 | biostudies-literature
| S-EPMC7572607 | biostudies-literature
| S-EPMC4632040 | biostudies-other